Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANJAY V VADGAMA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1679548556
CMS profile
257883
Location
SHERMAN OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,776.91

66 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,776.91 66

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANJAY V VADGAMA

NPI 1679548556 · CMS profile ID 257883

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SHERMAN OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679548556?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANJAY V VADGAMA, NPI 1679548556, CMS profile ID 257883. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679548556?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SANJAY V VADGAMA, NPI 1679548556, CMS profile ID 257883. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679548556?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SANJAY V VADGAMA, NPI 1679548556, CMS profile ID 257883, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–66 of 66 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679548556?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

66 matching records · $1,776.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 66 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–66 of 66.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $28.1903/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105844977 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.2802/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118106563 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $35.9002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080693976 CMS
United Therapeutics Corporation $20.5102/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149451073 CMS
Insmed, Inc. $5.0202/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089581658 CMS
Philips North America LLC $15.6202/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146904634 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $32.1302/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080693972 CMS
Amgen Inc. $14.4102/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116189508 CMS
GlaxoSmithKline, LLC. $27.9902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116737212 CMS
Pulmonx Corporation $25.4902/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087851668 CMS
Philips North America LLC $24.6401/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146904636 CMS
AstraZeneca Pharmaceuticals LP $16.5901/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104459580 CMS
Philips North America LLC $20.8301/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146904632 CMS
Mylan Specialty L.P. $26.2301/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147310608 CMS
Philips North America LLC $14.4001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146904630 CMS
Insmed, Inc. $32.6701/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089578946 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $866.69 44
PY2020 $724.09 38
PY2021 $810.02 41
PY2022 $928.27 41
PY2023 $1,210.25 56
PY2024 $1,776.91 66
PY2025 $836.72 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $375,793.01 69
PY2024 Principal investigator $528,421.99 61
PY2023 Principal investigator $591,081.49 89
PY2022 Principal investigator $564,903.92 14
PY2021 Principal investigator $561,907.76 28
PY2020 Principal investigator $560,689.27 20
PY2019 Principal investigator $158,937.06 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,957.15 12/11/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044062
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,350.35 11/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044060
Principal investigator 1 PFIZER INC. $10,073.00 11/04/2025 Non-covered Recipient Entity
California Medical Research Associates Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228738957
Principal investigator 1 SANOFI US SERVICES INC. $13,085.00 11/04/2025 Non-covered Recipient Entity
California Medical Research Inc
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226136648
Principal investigator 1 Verona Pharma, Inc. $7,245.22 11/03/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH AS
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891965
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $179.90 10/28/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244044110
Principal investigator 1 Verona Pharma, Inc. $3,556.80 10/15/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH AS
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891963
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,202.10 10/14/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044058
Principal investigator 1 Verona Pharma, Inc. $35,577.35 10/10/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH AS
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891961
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,617.30 09/25/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044056
Principal investigator 1 PFIZER INC. $2,650.00 09/11/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228743619
Principal investigator 1 Genentech, Inc. $1,500.00 09/10/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211582570
Principal investigator 1 Genentech, Inc. $6,452.00 09/10/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211582574
Principal investigator 1 Genentech, Inc. $3,702.00 09/10/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211582578
Principal investigator 1 Genentech, Inc. $1,000.00 09/10/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211582581
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $47,982.35 08/21/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044054
Principal investigator 1 GlaxoSmithKline, LLC. $2,300.00 08/20/2025 Non-covered Recipient Entity
VALIANCE CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118796
Principal investigator 1 GlaxoSmithKline, LLC. $4,068.00 08/20/2025 Non-covered Recipient Entity
VALIANCE CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118818
Principal investigator 1 Genentech, Inc. $9,706.00 08/01/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211582585
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,271.50 07/29/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185551899
Principal investigator 1 Verona Pharma, Inc. $8,000.00 07/23/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH AS
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891875
Principal investigator 1 Verona Pharma, Inc. $1,500.00 07/23/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH AS
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891877
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $24,291.80 06/24/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044052
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403264
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403269
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403273
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403275
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403299
Principal investigator 1 Chiesi USA, Inc. $221.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403329
Principal investigator 1 Chiesi USA, Inc. $221.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403343
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403354
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403357
Principal investigator 1 Chiesi USA, Inc. $221.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403361
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403364
Principal investigator 1 Chiesi USA, Inc. $351.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403370
Principal investigator 1 Chiesi USA, Inc. $351.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403375
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403378
Principal investigator 1 Chiesi USA, Inc. $221.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403383
Principal investigator 1 Chiesi USA, Inc. $351.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403387
Principal investigator 1 Chiesi USA, Inc. $351.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403391
Principal investigator 1 Chiesi USA, Inc. $351.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403395
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403399
Principal investigator 1 Chiesi USA, Inc. $273.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403403
Principal investigator 1 Chiesi USA, Inc. $221.00 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403407
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 06/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044108
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 06/19/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044106
Principal investigator 1 Chiesi USA, Inc. $1,235.00 06/13/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403065
Principal investigator 1 Chiesi USA, Inc. $6,561.75 06/13/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403077
Principal investigator 1 Chiesi USA, Inc. $2,648.75 06/13/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234403086
Principal investigator 1 Chiesi USA, Inc. $500.00 06/12/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234402764
Principal investigator 1 Chiesi USA, Inc. $1,000.00 06/12/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234402918
Principal investigator 1 Chiesi USA, Inc. $1,500.00 06/12/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234402922
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 06/12/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044104
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,500.00 04/30/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185551893
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,930.50 04/24/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044050
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 04/22/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044102
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 04/18/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044100
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,080.55 03/20/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044064
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35,753.25 02/27/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044066
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 02/27/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044098
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $272.80 02/21/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044096
Principal investigator 1 GlaxoSmithKline, LLC. $1,400.00 02/03/2025 Non-covered Recipient Entity
VALIANCE CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118801
Principal investigator 1 GlaxoSmithKline, LLC. $9,750.00 02/03/2025 Non-covered Recipient Entity
VALIANCE CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118808
Principal investigator 1 GlaxoSmithKline, LLC. $2,835.00 02/03/2025 Non-covered Recipient Entity
VALIANCE CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118813
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 01/28/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044094
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 01/22/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044092
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,868.09 01/17/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 No dispute reported 06/30/2026 1185551891
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,913.70 01/17/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185551897
Principal investigator 1 AstraZeneca Pharmaceuticals LP $162.60 01/08/2025 Non-covered Recipient Entity
CALIFORNIA MEDICAL RESEARCH ASSOCIATES
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185551895